Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue: 2009-2010

Historic Current Deferred Revenue for Madrigal Pharmaceuticals (MDGL) over the last 2 years, with Dec 2010 value amounting to $4.6 million.

  • Madrigal Pharmaceuticals' Current Deferred Revenue fell 27.76% to $3.3 million in Q3 2011 from the same period last year, while for Sep 2011 it was $3.3 million, marking a year-over-year decrease of 27.76%. This contributed to the annual value of $4.6 million for FY2010, which is 103.95% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Current Deferred Revenue of $4.6 million as of FY2010, which was up 103.95% from -$115.6 million recorded in FY2009.
  • Over the past 5 years, Madrigal Pharmaceuticals' Current Deferred Revenue peaked at $4.6 million during FY2010, and registered a low of -$115.6 million during FY2009.
  • Its 2-year average for Current Deferred Revenue is -$55.5 million, with a median of -$55.5 million in 2009.
  • Data for Madrigal Pharmaceuticals' Current Deferred Revenue shows a peak YoY soared of 103.95% (in 2010) over the last 5 years.
  • Over the past 2 years, Madrigal Pharmaceuticals' Current Deferred Revenue (Yearly) stood at -$115.6 million in 2009, then skyrocketed by 103.95% to $4.6 million in 2010.